CoGenesys, Inc.
12 articles about CoGenesys, Inc.
-
Craig Rosen, Ph.D., Biopharmaceutical Development Expert, Joins Phase Bioscience, Inc. as Executive Chairman
10/9/2008
-
Teva Pharmaceutical Industries Limited Says to Acquire CoGenesys, Inc. for $400 Million
1/22/2008
-
Vegenics Limited Licenses From CoGenesys, Inc. Antibodies Against VEGF-C for Applications Including Oncology
6/18/2007
-
CoGenesys, Inc. Announces the Achievement of Milestones Under License Agreements With PDL BioPharma, Inc. and Vegenics Limited
5/23/2007
-
CoGenesys, Inc. Expands Clinical Programs with Initiation of Phase 1-2a Trial of Neugranin in Cancer Patients
3/27/2007
-
The Day In Review: Two Big Deals To Start The New Year
1/3/2007
-
CoGenesys, Inc. Files To Begin Clinical Trials Of Neugranin For The Prevention Of Infections In Cancer Patients
1/3/2007
-
Dr. David U'Prichard Joins CoGenesys, Inc. Board Of Directors
12/19/2006
-
CoGenesys, Inc. Initiates Phase 1-2 Clinical Trial Of Cardeva In Patients With Heart Failure
10/11/2006
-
CoGenesys, Inc. Announces Worldwide License Agreement With Vegenics Limited
8/21/2006
-
CoGenesys, Inc. Receives FDA Clearance To Commence Clinical Trials Of Cardeva In Patients With Chronic Heart Failure
7/13/2006
-
CoGenesys, Inc. Raises $55 Million In Series A Financing
6/12/2006